BRAF and neoplasm: In mice, mutant BRAF-induced ERK activation is cancer stage-dependent with significantly higher levels of phosphorylated ERK in high-grade dysplasia and carcinoma 3, suggesting that different tumor stages may require different levels of p-ERK.